Pandemic & Infectious Disease — 2026-09-03
Recent weeks have seen significant developments in infectious disease management, including the FDA's approval of Moderna’s mRNA flu vaccine and GSK's advancement of its own mRNA flu vaccine into Phase 3 trials. Meanwhile, global health authorities continue to monitor active outbreaks of Ebola in the DRC and Uganda, as well as measles outbreaks in the Americas, while the CDC reports very low levels of acute respiratory illness in the US.
Pandemic & Infectious Disease — 2026-09-03
Active Outbreak Tracker
Ebola Disease (Bundibugyo Virus) — Democratic Republic of the Congo and Uganda
- Status: Active Outbreak / Public Health Emergency of International Concern
- Key Development: The ongoing outbreak caused by Bundibugyo virus in the DRC and Uganda remains a major focus for global health security. A recent CDC report details characteristics and monitoring efforts for this specific strain.
- Response: The WHO determined this epidemic a public health emergency of international concern in May 2026. Talks are underway between the DRC and WHO to expedite a multi-armed Phase 3 clinical trial of Ebola vaccines.
Map of Ebola outbreak areas
Ebola Outbreak: Current Situation | Ebola | CDC
cdc.gov
Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Measles — Americas Region
- Status: Epidemiological Alert
- Key Development: The Pan American Health Organization (PAHO) issued an epidemiological alert due to an increase in reported measles cases in the Americas Region in 2026. This increase is compounded by mass gatherings with broad international participation.
- Response: PAHO/WHO urges Member States to strengthen surveillance and vaccination coverage to prevent further spread.
Measles survivor boy in Nigeria
Ebola Outbreak: Current Situation | Ebola | CDC
cdc.gov
Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Respiratory Illnesses — United States
- Status: Very Low Activity
- Key Development: As of late August 2026, the amount of acute respiratory illness causing people to seek health care in the US is very low. CDC updates for flu and RSV will begin again in Fall 2026.
- Response: CDC continues to monitor respiratory virus activity levels and provides data channels for community-specific tracking.
CDC Respiratory Illness Alert Very Low
Ebola Outbreak: Current Situation | Ebola | CDC
cdc.gov
Current Epidemic Trends (Based on Rt) | CFA: Modeling and Forecasting | CDC
Global Measles Outbreaks | Global Measles Vaccination | CDC
Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
Measles Cases and Outbreaks | Measles (Rubeola) | CDC
Respiratory Illnesses Data Channel | Respiratory Illnesses | CDC
Vaccine & Treatment Pipeline
- mRNA Seasonal Influenza Vaccine (GSK): GSK announced it will advance its investigational mRNA seasonal flu vaccine candidate into a Phase 3 trial in September 2026. The vaccine targets both hemagglutinin and neuraminidase and outperformed licensed flu vaccines in a Phase 2 study.
- mRNA Flu Vaccine (Moderna): Moderna’s mRNA flu vaccine received FDA approval after Phase 3 data showed improved efficacy compared with standard flu vaccines.
- XFG-adapted COVID-19 Vaccine (Pfizer/BioNTech): Pfizer and BioNTech received U.S. FDA approval for their XFG-adapted COVID-19 vaccine for the 2026-2027 season, targeting the XFG variant. Shipping began immediately to ensure rapid access.
GSK mRNA Flu Vaccine
Expert Analysis
The recent approvals and advancements in mRNA technology for influenza and other diseases highlight a shift in vaccine development strategies. The FDA's approval of Moderna's mRNA flu vaccine marks a significant milestone, demonstrating improved efficacy over traditional vaccines. Following this, GSK's move to Phase 3 trials with its own mRNA candidate further underscores the modality's resurgence and potential to reshape seasonal vaccination approaches.
Meanwhile, the ongoing Ebola outbreak in the DRC and Uganda serves as a stark reminder of the persistent threat posed by emerging pathogens and the critical need for rapid diagnostic capabilities and vaccine deployment. The Lancet Regional Health – Europe noted that the Bundibugyo ebolavirus outbreak went undetected for months due to a lack of appropriate diagnostic tests, highlighting gaps in global health preparedness. Efforts to expedite Phase 3 clinical trials of Ebola vaccines in the region are crucial to addressing these vulnerabilities.
Global Health Security
The WHO's determination of the Ebola epidemic in the DRC and Uganda as a public health emergency of international concern underscores the seriousness of the situation and the need for coordinated international response. Additionally, PAHO's epidemiological alert regarding measles in the Americas emphasizes the importance of maintaining high vaccination coverage and robust surveillance systems to prevent outbreaks from spreading across borders.
What to Watch Next
- GSK's mRNA Flu Vaccine Phase 3 Trial: The initiation and progress of this trial will be closely watched as it could provide another highly effective option for seasonal influenza prevention.
- Ebola Vaccine Trial in DRC: Updates on the start and progress of the multi-armed Phase 3 clinical trial for Ebola vaccines in the DRC will be critical for assessing potential solutions to the ongoing outbreak.
- Fall 2026 Respiratory Virus Season: As the CDC prepares to resume flu and RSV updates, monitoring the onset and severity of the upcoming respiratory illness season will be essential for public health planning.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
